Preventing and treating biologic-associated opportunistic infections

Nature Reviews Rheumatology

Volumn 5, Issue 7, 2009, Pages 405-410

  Winthrop, Kevin L ^a   Chiller, Tom ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; GAMMA INTERFERON; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED DISORDER; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; OPPORTUNISTIC INFECTION; TUBERCULIN TEST; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA; OPPORTUNISTIC INFECTIONS; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349577776     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.105     Document Type: Article

References (28)

1. Furst, D. E. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann. Rheum. Dis. 67 (Suppl. 3), iii2-iii25 (2008).
2. Winthrop, K. L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Prat. Rheumatol. 2, 602–610 (2006).
3. Saag, K. G. et al. American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 15, 762–784 (2008).
4. Tissot, F., Zanetti, G., Francioli, P., Zellweger, J. P. & Zysset, F. Influence of bacilli calmette–Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin. Infect. Dis. 40, 211–217 (2005).
5. Pai, M., Riley, L. W. & colford, J. M. Jr. Interferongamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4, 761–776 (2004).
6. Beglinger, C. et al. Screening for tuberculosis infection before the initiation of an anti-tNF-alpha therapy. Swiss Med. Wkly 137, 620–622 (2007).
7. Ponce de Leon, D. et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (tB) infection in patients with rheumatoid arthritis in a tB-endemic population. J. Rheumatol. 35, 776–781 (2008).
8. Matulis, G., Juni, P., villiger, P. M. & Gadola, S. D. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases—performance of a mycobacterium tuberculosis antigen specific iFN-gamma assay. Ann. Rheum. Dis. 67, 84–90 (2008).
9. Vassilopoulos, D., stamoulis, N., Hadziyannis, E. & Archimandritis, A. J. Usefulness of enzyme-linked immunospot assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J. Rheumatol. 35, 1271–1276 (2008).
10. Piana, F. et al. Use of a t-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur. Respir. J. 28, 31–34 (2006).
11. Lalvani, A. & Millington, K. A. screening for tuberculosis infection prior to initiation of antitNF therapy. Autoimmun. Rev. 8, 147–152 (2008).
12. Hamdi, H. et al. Inhibition of anti-tuberculosis t-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res. Ther. 8, r114 (2006).
13. Winthrop, K. L., siegel, J. N., Jereb, J., taylor, Z. & iademarco, M. F. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum. 52, 2968–2974
14. British thoracic society standards of care committee. Bts recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-tNF-alpha treatment. Thorax 60, 800–805 (2005).
15. Canadian tuberculosis committee. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. Can. Commun. Dis. Rep. 34, 1–13 (2008).
16. [No authors listed] targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 161, s221–s247 (2000).
17. CDC & American thoracic society. Update: adverse event data and revised American thoracic society/cDc recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United states, 2003. MMWR Morb. Mortal. Wkly Rep. 52, 735–739 (2003).
18. Carmona, L. et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52, 1766–1772 (2005).
19. American thoracic society, CDC & infectious Diseases society of America. Treatment of tuberculosis. MMWR Reccom. Rep. 52, 1–77 (2003).
20. Winthrop, K. L., Yamashita, S., Beekman, S. E. & polgreen, P. M. Mycobacterial and other serious infections in patients receiving antitNF and other newly approved biologic therapies; case-finding via the emerging infections Network. Clin. Infect. Dis. 46, 1738–1740 (2008).
21. Denis, B. et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (tNF)-alpha antagonist therapy: safe re-initiation of tNF-alpha blockers after appropriate anti-tuberculous treatment. Clin. Microbiol. Infect. 14, 183–186 (2008).
22. Wheat, L. J. et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious Diseases society of America. Clin. Infect. Dis. 45, 807–825 (2007).
23. McKinsey, D. S. et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National institute of Allergy and infectious Diseases Mycoses study Group. Clin. Infect. Dis. 28, 1049–1056 (1999).
24. vail, G. M. et al. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl. Infect. Dis. 4, 148–151 (2002).
25. Valdivia, L. et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg. Infect. Dis. 12, 958–962 (2006).
26. Chiller, T. M., Galgiani, J. N. & Stevens, D. A. Coccidioidomycosis. Infect. Dis. Clin. North Am. 17, 41–57, viii (2003).
27. Bergstrom, L. et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 50, 1959–1966 (2004).
28. Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E. & Beenhouwer, D. O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38, 1261–1265 (2004).